{"id":"NCT00132873","sponsor":"Jazz Pharmaceuticals","briefTitle":"Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy","officialTitle":"Long-Term, Open-Label, Multi-Center Extension Trial of Xyrem® (Sodium Oxybate) Oral Solution for the Treatment of Narcolepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-10","primaryCompletion":"2007-09","completion":"2007-12","firstPosted":"2005-08-22","resultsPosted":"2013-11-25","lastUpdate":"2013-11-25"},"enrollment":59,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":null},"conditions":["Narcolepsy"],"interventions":[{"type":"DRUG","name":"Xyrem (sodium oxybate) oral solution","otherNames":[]}],"arms":[],"summary":"This is a long-term, open-label, extension of the OMC-SXB-7 trial. Participants from the OMC-SXB-7 open-label trial may be entered without any requirement as to length of participation in that trial.\n\nApproximately 70 patients are expected to participate at up to 6 investigative centers located in Canada. The trial will continue for up to 24 months or until marketing approval, whichever occurs sooner.","primaryOutcome":{"measure":"Adverse Experiences","timeFrame":"continuous","effectByArm":[{"arm":"Xyrem (Sodium Oxybate)","deltaMin":54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":58},"commonTop":["Nasopharyngitis","Urinary Tract Infection","Hypertension","Influenza","Pain In Extremity"]}}